

UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In Re. Zosano Pharma Corporation

Case No. 22-10506

Debtor(s)

§
§
§
§

Jointly Administered

Monthly Operating Report

Chapter 11

Reporting Period Ended: 11/30/2022

Petition Date: 06/01/2022

Months Pending: 6

Industry Classification: 3 2 5 4

Reporting Method: Accrual Basis

Cash Basis

Debtor's Full-Time Employees (current):

0

Debtor's Full-Time Employees (as of date of order for relief):

15

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- Statement of cash receipts and disbursements
Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
Statement of operations (profit or loss statement)
Accounts receivable aging
Postpetition liabilities aging
Statement of capital assets
Schedule of payments to professionals
Schedule of payments to insiders
All bank statements and bank reconciliations for the reporting period
Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Dennis A. Meloro
Signature of Responsible Party

03/14/2023
Date

Dennis A. Meloro (DE Bar No. 4435)
Printed Name of Responsible Party

222 Delaware Avenue, Suite 1600
Wilmington, DE 19801
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore § 1320.4(a)(2) applies.



221050623031400000000001

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$4,807,440	
b.	Total receipts (net of transfers between accounts)	\$1	\$1,429,877
c.	Total disbursements (net of transfers between accounts)	\$255,483	\$2,605,364
d.	Cash balance end of month (a+b-c)	\$4,551,958	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$255,483	\$2,605,364
Part 2: Asset and Liability Status		Current Month	
(Not generally applicable to Individual Debtors. See Instructions.)			
a.	Accounts receivable (total net of allowance)	\$0	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0	
c.	Inventory (Book <input checked="" type="radio"/> Market <input type="radio"/> Other <input type="radio"/> (attach explanation))	\$0	
d.	Total current assets	\$4,916,065	
e.	Total assets	\$5,073,512	
f.	Postpetition payables (excluding taxes)	\$541,430	
g.	Postpetition payables past due (excluding taxes)	\$312,854	
h.	Postpetition taxes payable	\$0	
i.	Postpetition taxes past due	\$0	
j.	Total postpetition debt (f+h)	\$541,430	
k.	Prepetition secured debt	\$0	
l.	Prepetition priority debt	\$18,147	
m.	Prepetition unsecured debt	\$11,528,639	
n.	Total liabilities (debt) (j+k+l+m)	\$12,088,216	
o.	Ending equity/net worth (e-n)	\$-7,014,704	
Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$2,950
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$2,950
Part 4: Income Statement (Statement of Operations)		Current Month	Cumulative
(Not generally applicable to Individual Debtors. See Instructions.)			
a.	Gross income/sales (net of returns and allowances)	\$0	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$0	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$42,394	
f.	Other expenses	\$7,627	
g.	Depreciation and/or amortization (not included in 4b)	\$0	
h.	Interest	\$-1	
i.	Taxes (local, state, and federal)	\$0	
j.	Reorganization items	\$85,562	
k.	Profit (loss)	\$-135,582	\$-16,974,579

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

Part 5: Professional Fees and Expenses

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>		\$0	\$0	\$208,673	\$1,249,811
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i	Kurtzman Carson Consultants L	Other	\$0	\$0	\$208,673	\$627,423
ii	Greenberg Traurig, LLP	Lead Counsel	\$0	\$0	\$0	\$458,163
iii	SierraConstellation Partners LL	Financial Professional	\$0	\$0	\$0	\$164,225
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
b.	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>		\$0	\$0	\$0	\$2,617	
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	BPM LLP	Financial Professional	\$0	\$0	\$0	\$2,617
	ii						
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
xiii							
xiv							

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxvii						
lxxix						
lxxx						
lxxxii						
lxxxii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

	xcix					
	c					
c.	All professional fees and expenses (debtor & committees)			\$0	\$0	\$0

Part 6: Postpetition Taxes		Current Month	Cumulative
a.	Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b.	Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c.	Postpetition employer payroll taxes accrued	\$0	\$0
d.	Postpetition employer payroll taxes paid	\$0	\$27,143
e.	Postpetition property taxes paid	\$0	\$0
f.	Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g.	Postpetition other taxes paid (local, state, and federal)	\$0	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes No
- c. Were any payments made to or on behalf of insiders? Yes No
- d. Are you current on postpetition tax return filings? Yes No
- e. Are you current on postpetition estimated tax payments? Yes No
- f. Were all trust fund taxes remitted on a current basis? Yes No
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes No
- h. Were all payments made to or on behalf of professionals approved by the court? Yes No N/A
- i. Do you have:
 - Worker's compensation insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - Casualty/property insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
 - General liability insurance? Yes No
 - If yes, are your premiums current? Yes No N/A (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes No
- k. Has a disclosure statement been filed with the court? Yes No
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes No

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

Part 8: Individual Chapter 11 Debtors (Only)

- a. Gross income (receipts) from salary and wages \$0
- b. Gross income (receipts) from self-employment \$0
- c. Gross income from all other sources \$0
- d. Total income in the reporting period (a+b+c) \$0
- e. Payroll deductions \$0
- f. Self-employment related expenses \$0
- g. Living expenses \$0
- h. All other expenses \$0
- i. Total expenses in the reporting period (e+f+g+h) \$0
- j. Difference between total income and total expenses (d-i) \$0
- k. List the total amount of all postpetition debts that are past due \$0
- l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? Yes No
- m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).


I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Steven Lo
 Signature of Responsible Party
President and CEO
 Title


Steven Lo
 Printed Name of Responsible Party
03/14/2023
 Date

Debtor's Name Zosano Pharma Corporation


Case No. 22-10506




PageOnePartOne



PageOnePartTwo




PageTwoPartOne



PageTwoPartTwo

Debtor's Name Zosano Pharma Corporation


Case No. 22-10506



Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506



PageThree



PageFour

**Zosano Pharma - Schedule of Payments to Professionals
For the Month Ended November 30, 2022**

<u>Name of Professional</u>	<u>Role</u>	<u>Date of Retention</u>	<u>Retainer Received</u>	<u>Court Approved ⁽¹⁾</u>				<u>Retainer Applied</u>				<u>Paid by Estate</u>				
				<u>Compensation</u>	<u>Expenses</u>	<u>Current Period</u>	<u>Cumulative</u>	<u>Compensation</u>	<u>Expenses</u>	<u>Current Period</u>	<u>Cumulative</u>	<u>Compensation</u>	<u>Expenses</u>	<u>Current Period</u>	<u>Cumulative</u>	
Kurtzman Carson Consultants LLC	Claims and Noticing Agent	6/1/2022	\$ 50,000	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 13,260	\$ 132,116	\$ 76,557	\$ 208,673	\$ 627,423
Greenberg Traurig, LLP	Counsel to Debtor	6/1/2022	\$ 491,492	\$ -	\$ -	\$ -	\$ 458,163	\$ -	\$ -	\$ -	\$ 458,163	\$ -	\$ -	\$ -	\$ -	\$ -
SierraConstellation Partners LLC	Financial Advisor	6/1/2022	\$ 165,345	\$ -	\$ -	\$ -	\$ 164,225	\$ -	\$ -	\$ -	\$ 164,225	\$ -	\$ -	\$ -	\$ -	\$ -
BPM LLP	Tax Professional	9/2/2022	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 2,617

(1) Per the order authorizing retention of Kurtzman Carson Consultants LLC (KCC) as Claims and Noticing Agent (Docket No. 23), the Debtor is authorized to compensate KCC for its services and expenses without the need for KCC to file fee applications or otherwise seek Court approval.

Zosano Pharma Corporation - Monthly Operating Report**Schedule of Cash Receipts and Disbursements**

Case No. 22-10506

Reporting Period: July 1st through November 30th, 2022

(\$USD)

	Month Ending 6/30/2022	Month Ending 7/31/2022	Month Ending 8/31/2022	Month Ending 9/30/2022	Month Ending 10/31/2022	Month Ending 11/30/2022	Cumulative Total
Cash Flow							
Receipts							
Receipts	\$ 147,074	\$ 229,207	\$ 1,000,004	\$ 5,008	\$ 48,582	\$ 1	\$ 1,429,877
Operating Disbursements							
Payroll	314,677	227,404	165,792	77,167	19,430	14,981	819,451
Benefits	41,852	51,191	13,955	-	60	-	107,058
Rent	-	186,946	-	300,000	-	-	486,946
Utilities	4,382	23,136	1,791	578	1,252	-	31,140
Insurance	-	9,389	-	-	-	-	9,389
Taxes	-	204,029	2,682	57	-	-	206,768
IT and Other Essential Services	9,257	22,425	9,512	13,608	12,124	9,126	76,052
Board fees	-	70,908	17,178	8,333	-	-	96,420
Other Operating Disbursements	8,124	18,278	2,874	919	2,806	5,305	38,306
Total Operating Disbursements	\$ 378,292	\$ 813,707	\$ 213,785	\$ 400,662	\$ 35,673	\$ 32,518	\$ 1,874,635
Operating Cash Flow	\$ (231,218)	\$ (584,500)	\$ 786,219	\$ (395,654)	\$ 12,910	\$ (32,516)	\$ (444,759)
Cumulative Operating Cash Flow	\$ (231,218)	\$ (815,718)	\$ (29,498)	\$ (425,152)	\$ (412,242)	\$ (444,759)	\$ (444,759)
Non-Operating Disbursements							
Debtor Counsel	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	-
Strategic Process / Debtor Financial Advisor	-	-	-	-	-	-	-
United States Trustee	-	250	-	1,263	-	14,293	15,806
Claims Agent	-	-	108,709	160,684	149,357	208,673	627,423
Other	-	-	-	-	-	-	-
Sales Agent	-	87,500	-	-	-	-	87,500
Contingency	-	-	-	-	-	-	-
Total Non-Operating Disbursements	\$ -	\$ 87,750	\$ 108,709	\$ 161,947	\$ 149,357	\$ 222,966	\$ 730,729
Net Cash Flow	\$ (231,218)	\$ (672,250)	\$ 677,510	\$ (557,601)	\$ (136,447)	\$ (255,482)	\$ (1,175,488)
Cumulative Net Cash Flow	\$ (231,218)	\$ (903,468)	\$ (225,957)	\$ (783,558)	\$ (920,006)	\$ (1,175,488)	\$ (1,175,488)
Cash Balance							
Beginning Balance	\$ 5,727,445	\$ 5,496,228	\$ 4,823,978	\$ 5,501,488	\$ 4,943,887	\$ 4,807,440	5,727,445
Net Cash Flow	(231,218)	(672,250)	677,510	(557,601)	(136,447)	(255,482)	(1,175,488)
Ending Balance	\$ 5,496,228	\$ 4,823,978	\$ 5,501,488	\$ 4,943,887	\$ 4,807,440	\$ 4,551,958	\$ 4,551,958
Restricted Cash	\$ 457,447	\$ 457,447	\$ 454,580	\$ 154,580	\$ 154,580	\$ 154,580	\$ 154,580
Available Cash	\$ 5,038,780	\$ 4,366,530	\$ 5,046,908	\$ 4,789,307	\$ 4,652,860	\$ 4,397,378	\$ 4,397,378



Balance Sheet

12/22/2022

05:26:47

USD

Report Analysis Code	11-2022 Closing Balance
Assets	
Current assets	
Cash and cash equivalents	
10012 Cash, SVB ZPC Checking	4,342,772.25
10013 Cash, SVB (IGOE Admin)	51,738.09
20220 Supplier PIP Account	(2,556.17)
TOTAL Cash and cash equivalents	4,391,954.17
Inventory	
12100 Raw Material Inventory	967,435.52
12199 Pre-Launch Inv-Reserve	(967,435.52)
TOTAL Inventory	0.00
Prepaid expenses and other current assets	
11160 Accounts Rec - Other	261,148.43
13111 Short-Term Deposits	0.00
13131 Prepaid Exp, Insurance	0.00
13181 Prepaid Expenses, Other	114,312.34
13182 Prepaid Software - ST	99,293.26
14000 Other Current Assets	49,356.70
TOTAL Prepaid expenses and other current assets	524,110.73
TOTAL Current assets	4,916,064.90
Restricted cash	
Restricted cash	
10120 Restricted Cash	157,447.48
TOTAL Restricted cash	157,447.48
TOTAL Restricted cash	157,447.48
Property and equipment, net	
Property and equipment	
16211 Manufacturing Equipment	11,572,297.37
16221 MFG Equip, Tools/Dies	3,515,445.03
16311 Furniture & Fixtures	98,901.70
16411 Office Equipment	45,736.00
16413 Office Equipment - Lease	24,604.00
16511 Laboratory Equipment	1,374,574.67
16611 Computer Equipment	135,398.04
16652 Computers - Leased	18,712.89
16711 Software	34,436.38
16811 Leasehold Improvements	18,074,362.00
16912 Fixed Assets CIP	0.00
16915 Fixed Assets Clearing	(451,891.46)
16916 Mfg Equip - Clearing	(11,572,297.37)

16917 MfgTools/Dies - Clearing	(3,515,445.13)
16918 Furn & Fixt - Clearing	(98,901.70)
16919 Lab Equip - Clearing	(1,374,574.67)
16920 Comptr Equip - Clearing	(135,398.04)
TOTAL Property and equipment	17,745,959.71
Accumulated depreciation	
17211 Accum Depr, MFG Equip	(9,848,160.67)
17221 Accum Depr, Tools/Dies	(1,593,344.98)
17311 Accum Depr, Furn & Fixt	(45,209.26)
17411 Accum Depr, Office Equip	(45,736.00)
17413 Accum Depr, OE - Leased	(24,604.00)
17511 Accum Depr, Lab Equip	(998,161.83)
17611 Accum Depr, Comp Equip	(115,760.18)
17652 Accum Depr. Comp - Lease	(18,712.89)
17711 Accum Depr, Software	(33,787.85)
17811 Accum Depr, LH Improv	(17,761,858.25)
17915 Accum Depr, Clearing	138,739.12
17916 AccDep MfgEqu - Clearing	9,848,160.67
17917 AccDep Tool/Die-Clearing	1,593,344.98
17918 AccDep Furn/Fix - Cleari	45,209.26
17919 AccDep LabEquip-Clearing	998,161.83
17920 AccDep Comptr - Clearing	115,760.18
TOTAL Accumulated depreciation	(17,745,959.87)
TOTAL Property and equipment, net	(0.16)
Operating lease right-of-use asset	
Operating lease right-of-use asset	
18000 Op. Lease ROU Assets	0.00
TOTAL Operating lease right-of-use asset	0.00
TOTAL Operating lease right-of-use asset	0.00
Deferred tax assets	
Deferred tax assets	
19910 Deferred Tax Asset	39,380,141.00
19911 Def. Tax Asset Allowance	(38,458,373.00)
19912 Deferred tax liability	(921,768.00)
TOTAL Deferred tax assets	0.00
TOTAL Deferred tax assets	0.00
TOTAL Assets	5,073,512.22
Liabilities & Equity	
Liabilities	
Current liabilities	
Accounts payable	
20100 Accounts Payable (Trade)	6,212,252.43
20120 AP - Unvouchered/Adj	248,993.79
20130 AP Unvouchered	0.00
20200 Uninvoiced Recpt - Inv	(0.01)
TOTAL Accounts payable	6,461,246.21
Accrued compensation	

21110 Vacation Liability	92,060.95
21130 Flex Contrib - Current	0.00
21140 Voluntary Life Insurance	0.00
21150 Payroll Clearing	0.00
TOTAL Accrued compensation	92,060.95
Build-to-suit obligation, current portion	
29216 Trinity Credit Line	0.00
TOTAL Build-to-suit obligation, current portion	0.00
Operating lease liabilities, current portion	
22200 Operating Lease Liab-ST	1,671,759.09
TOTAL Operating lease liabilities, current portion	1,671,759.09
Other accrued liabilities	
20180 Miscellaneous Accrual	744,671.63
23200 Other ST Liability	1,071,935.48
25110 Legal - Accrual	33,557.75
25130 Use Tax Payable (CA)	0.00
TOTAL Other accrued liabilities	1,850,164.86
TOTAL Current liabilities	10,075,231.11
Operating Lease Liabilities, long -term portion	
29230 Operating Lease Liab-LT	2,012,985.09
TOTAL Operating Lease Liabilities, long -term portion	2,012,985.09
Other long-term liabilities	
TOTAL Other long-term liabilities	0.00
Deferred rent	
TOTAL Deferred rent	0.00
TOTAL Liabilities	12,088,216.20
Equity	
Preferred stock	
TOTAL Preferred stock	0.00
Common stock	
31200 Common Stock (Par)	490.23
TOTAL Common stock	490.23
Additional paid In capital	
31111 APIC, Common	306,711,014.06
32213 APIC, Warrant	1,438,718.34
32223 Issuance Costs, Common	(12,822,167.57)
32233 Iss Costs, Common (IPO)	(5,895,000.97)
32251 Realized (Gain) Loss	120,309,803.89
32255 Unrealized FX Loss	(9,600.11)
TOTAL Additional paid In capital	409,732,767.64
Accumulated deficit	
39121 Retained Earnings CY	(54,633,203.21)
39123 Retained Earnings	(362,114,758.64)
TOTAL Accumulated deficit	(416,747,961.85)
Accumulated other comprehensive (income) loss	
TOTAL Accumulated other comprehensive (income) loss	0.00
Suspense	

TOTAL Suspense	0.00
TOTAL Equity	(7,014,703.98)
TOTAL Liabilities & Equity	5,073,512.22

ZOSANO PHARMA CORPORATION
STATEMENT OF OPERATIONS
(in thousands)

	Month of November 30, 2022	Cumulative Post-Petition
	(unaudited)	(unaudited)
Service revenue	\$ -	\$ (6)
Operating expenses:		
Cost of service revenue	-	20
Research and development	8	2,291
General and administrative	128	6,190
Loss on impairment of assets	-	-
Total operating expenses	136	8,501
Loss from operations	(136)	(8,507)
Other income (expense):		
Interest income	0	1
Interest expense	-	0
Other income (expense), net	-	(8,469)
Loss before provision for income taxes	(136)	(16,974)
Provision for income taxes	-	-
Net loss	(136)	(16,974)